State of the Union: Advances in the Management of mUC - a podcast by ReachMD

CME credits: 0.50

Valid until: 30-08-2022

Claim your CME credit at https://reachmd.com/programs/cme/state-union-advances-management-muc/12764/

Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.

This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD